Lakewood-Amedex Biotherapeutics Inc.(LABT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LABT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of LABT by reported 13-F value include Marex Group plc, UBS Group AG, Tower Research Capital (TRC), based on the most recent SEC filings. LABT trades on the Nasdaq exchange and files with the SEC under CIK 2079272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lakewood-Amedex Biotherapeutics Inc. directly from SEC EDGAR.

Net Income

$-3.8M

Institutions holding LABT

Institutional investors reporting a position in Lakewood-Amedex Biotherapeutics Inc. on SEC Form 13F.
InstitutionSharesValueReported
Marex Group plc48,167$151.2K2026-06-30
UBS Group AG4,098$12.9K2026-06-30
Tower Research Capital (TRC)624$2.0K2026-06-30
OSAIC138$433.002026-06-30
HRT FINANCIAL44,782$140.002026-06-30
Ronald Blue11$35.002026-06-30
SEC EDGAR: CIK 2079272 →
LABT

Lakewood-Amedex Biotherapeutics Inc.

LABT
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-3.77M

EPS (Diluted)

Q2 2026
EDGAR

$-2.75

Top Institutional Holders

as of Q2 2026
$166.7K total
Marex Group plc
$151.2K--
UBS Group AG
$12.9K--
Tower Research Capital LLC (TRC)
$2.0K--
OSAIC HOLDINGS, INC.
$433--
HRT FINANCIAL LP
$140--
Ronald Blue Trust, Inc.
$35--

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…